Key result
Ticagrelor increases platelet membrane cholesterol ~2 percentage points vs control, rigidifying the membrane.
Why the study?
Data concerning platelet plasma membrane lipid composition need updating, and data on the impact of antiplatelet agents on membrane composition remain sparse.
Ticagrelor and its active metabolite induce rigidification and alter arachidonic acid availability in the platelet plasma membrane, providing insights into structural antiplatelet mechanisms beyond direct P2Y12 receptor antagonism.
Answers are grounded in this paper and cite their sources.
Caution against clinical extrapolation from animal platelets; extends mechanistic insights but leaves relevance to human ACS outcomes open.
Lipids contained in the plasma membrane of platelets play an important role in platelet function. Modifications in the lipid composition can fluidify or rigidify the environment around embedded receptors, in order to facilitate the access of the receptor by the drug. However, data concerning the lipid composition of platelet plasma membrane need to be updated. In addition, data on the impact of drugs on plasma membrane composition, in particular antiplatelet agents, remain sparse. After isolation of platelet plasma membrane, we assessed, using lipidomics, the effect of ticagrelor, a P2Y12 antagonist, and its active metabolite on the lipid composition of these plasma membranes. We describe the exact lipid composition of plasma membrane, including all sub-species. Ticagrelor and its active metabolite significantly increased cholesterol and phosphatidylcholine ether with short saturated acyl chains 16:0/16:0, and decreased phosphatidylcholine, suggesting overall rigidification of the membrane. Furthermore, ticagrelor and its active metabolite decreased some arachidonylated plasmalogens, suggesting a decrease in availability of arachidonic acid from the membrane phospholipids for synthesis of biologically active mediators. To conclude, ticagrelor and its active metabolite seem to influence the lipid environment of receptors embedded in the lipid bilayer and modify the behavior of the plasma membrane.
No takes yet. Share an insight, caveat, or question.
Lagoutte‐Renosi et al. (2021) studied Healthy human platelets (in vitro). Ticagrelor and its active metabolite AR-C124910XX vs. Control (PBS) was evaluated on Cholesterol proportion in platelet plasma membrane (p=<0.001). Ticagrelor significantly increased cholesterol in the platelet plasma membrane compared to control, suggesting an overall rigidification of the membrane.
Synapse has enriched 10 related papers. Consider them for comparative context: